US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Super League Gaming Inc.

0.1099

-0.0049-4.27%

Pre-market: 0.11290.0030+2.73%09:00 EDT

Volume:4.47M

Turnover:483.20K

Market Cap:3.61M

PE:-0.07

High:0.1143

Open:0.1137

Low:0.1040

Close:0.1148

Loading ...

Overview Company News Filings

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

This Super League Enterprise Insider Increased Their Holding By 46% Last Year

Simply Wall St.

Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Royalty Pharma Announces R&D Funding Collaboration With Biogen

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?

Jail, caning for teen in SLE bike chase that killed LTA officer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Press Release: Autolus Therapeutics Provides Business Updates and 2025 Overview

Autolus Therapeutics Provides Business Updates and 2025 Overview

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

Press Release: Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SLE/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":0.1099,"timestamp":1750104000000,"preClose":0.1148,"halted":0,"volume":4471324,"hourTrading":{"tag":"盘前","latestPrice":0.1129,"preClose":0.1099,"latestTime":"09:00 EDT","volume":105109,"amount":12079.754831819999,"timestamp":1750165211107},"delay":0,"floatShares":29862399,"shares":32824123,"eps":-1.68411,"marketStatus":"Pre-Mkt","change":-0.0049,"latestTime":"06-17 09:00:19 EDT","open":0.1137,"high":0.1143,"low":0.104,"amount":483200.33504599996,"amplitude":0.089721,"askPrice":0.113,"askSize":1200,"bidPrice":0.1111,"bidSize":850,"shortable":3,"etf":0,"ttmEps":-1.68411,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1750167000000},"marketStatusCode":1,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":0.1099,"preHourTrading":{"tag":"盘前","latestPrice":0.1129,"preClose":0.1099,"latestTime":"09:00 EDT","volume":105109,"amount":12079.754831819999,"timestamp":1750165211107},"postHourTrading":{"tag":"盘后","latestPrice":0.113,"preClose":0.1099,"latestTime":"19:59 EDT","volume":286196,"amount":31571.889609,"timestamp":1750118362810},"volumeRatio":0.8637924149305629},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":29862399,"roa":"-71.33%","roe":"-1235.06%","lyrEps":-2.351262,"volumeRatio":0.8637924149305629,"shares":32824123,"dividePrice":0,"high":0.1143,"amplitude":0.089721,"preClose":0.1148,"low":0.104,"week52Low":0.104,"pbRate":"-1.04","psRate":"0.25","week52High":1.64,"institutionHeld":0,"latestPrice":0.1099,"committee":-0.170732,"eps":-1.68411,"divideRate":0,"volume":4471324,"delay":0,"ttmEps":-1.68411,"open":0.1137,"prevYearClose":0.6175,"prevWeekClose":0.1148,"prevMonthClose":0.195,"prevQuarterClose":0.235,"fiveDayClose":0.13,"twentyDayClose":0.1775,"sixtyDayClose":0.3463},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517792973","title":"Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517792973","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517792973?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:01","pubTimestamp":1741208460,"startTime":"0","endTime":"0","summary":"Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE. Completed Type D Meeting with FDA to Enable FT819 Off-the-Shelf CAR T-cell Dose Expansion in Additional B Cell-mediated Autoimmune Diseases. First FT819 Off-the-Shelf CAR T-cell Patient Treated without Conditioning Chemotherapy as Add-on to Maintenance Therapy in SLE. Phase 1 Dose Expansion Initiated for SLE using Flu-free Conditioning Regimen. Based on clinical data from the first three patients treated with FT819 in its ongoing multi-center, Phase 1 clinical trial for moderate-to-severe systemic lupus erythematosus  , the Company has initiated dose expansion in up to 10 patients at 360 million cells. The dose expansion stage is designed to evaluate the safety and efficacy of a fludarabine -free conditioning regimen, consisting of either bendamustine alone or cyclophosphamide alone, followed by a single dose of FT819. The Company is also a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-reports-fourth-quarter-210100391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU2463526074.USD","SITC","FATE","BK4112","CAR","IE00B66KJ199.SGD","BK4022","IE00B19Z4B17.USD","BK4077","IE0031619046.USD","LU2065731478.USD","BK4109","IE00B7SZL793.SGD","IIM","SLE","BK4006","CRS","BK4230","BK4231","BK4080","ASH","TRAC"],"gpt_icon":0},{"id":"2514350959","title":"Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris","url":"https://stock-news.laohu8.com/highlight/detail?id=2514350959","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514350959?lang=en_us&edition=fundamental","pubTime":"2025-02-28 08:05","pubTimestamp":1740701100,"startTime":"0","endTime":"0","summary":"Cenerimod is a novel oral S1P1 receptor modulator with potential to be a first- or best-in-class therapy for multiple autoimmune diseases. Viatris previously acquired rights to cenerimod in all other territories from Idorsia, and now has exclusive global rights. Nxera will receive an upfront payment of US$10 million from Viatris, and is eligible to receive a further milestone payment upon regulatory approval of cenerimod in Japan plus royalties on net sales in the assigned territories. Viatris will be the exclusive owner of cenerimod rights in Japan and APAC . Viatris gained exclusive rights to cenerimod in all other territories from Idorsia through a research and development agreement signed in February 2024 and following this agreement with Nxera, now owns exclusive global rights to the candidate.About ViatrisViatris Inc. is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically add","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nxera-pharma-assigns-japan-apac-000500896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","LU2087621335.USD","UK","BK4205","SLE","BK4588","BK4583","BK4585","SOLTF","VTRS","BK4007","BK4528","LU1839511570.USD","BK4233"],"gpt_icon":0},{"id":"2514806912","title":"Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514806912","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514806912?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif. & BOSTON, February 27, 2025----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration  has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with systemic sclerosis .Fast Track Designation is a process designed to facilitate development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.This press release contains \"forward-looking statements\" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"target,\" \"would\" and similar expressions are intended to identify forward-looking statements, althoug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-receives-fda-fast-120000634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4605","LU2272731600.USD","SLE","BK4139","LU0724618433.USD","LU0082616367.USD","LU2458330243.SGD","LU1244550494.USD","IE0009356076.USD","LU2237443978.SGD","ACET","LU1992135472.HKD","LU2237443622.USD","BK4077","LU2458330169.SGD","BK4515","LU1861219969.SGD","LU2272731782.SGD","CAR","LU2237443382.USD","LU2237438978.USD","FAST","LU0109392836.USD","LU1861214812.USD","LU1244550577.SGD","LU1670711040.USD","LU1244550221.USD","LU1074936037.SGD","BK4512","BK4561","IE00B5949003.HKD","LU1670710661.SGD","ADI","BK4230","LU1670710588.SGD","IE00BD6J9T35.USD","LU0124384867.USD","LU1803068979.SGD","LU2298322129.HKD","LU0444971666.USD","LU1642822529.SGD","LU2237443549.SGD","LU0719512351.SGD","IE00BZ199S13.USD","BK4141","LU1978683503.SGD","LU1815336760.USD","LU0314104364.USD","LU0889565833.HKD","LU1992135399.USD"],"gpt_icon":0},{"id":"2514180530","title":"Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514180530","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514180530?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus  expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S.Zipalertinib pivotal Phase 2b study met primary endpoint; full results mid-year 2025 and NDA submission planned H2 2025, pending regulatory discussions. Cash and investments of $606.9 million as of December 31, 2024, continues to provide runway into 2028. CAMBRIDGE, Mass., Feb. 27, 2025  -- Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2024.CLN-978 : Systemic lupus erythematosus and rheumatoid arthritis. The global Phase 1 study in moderate to severe SLE is ongoing with site expansion in the United States, Europe and Australia, and the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-provides-corporate-reports-120000914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RA","BK4077","CGEM","SLE","BK4139"],"gpt_icon":0},{"id":"2514054798","title":"On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2514054798","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514054798?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"Revenue in 2024 increased to  6.15 billion, a plus of 17% ,Net sales were up by 15% to 5.61 billion  driven by a strong, triple- and double-digit growth performance of newly launched growth drivers: BIMZELX, EVENITY, FINTEPLA, RYSTIGGO and ZILBRYSQ as well as solid contribution from CIMZIA and BRIVIACT reaching its peak sales two years ahead of target. Underlying profitability  went up to  1.48 billion, a plus of 9% ,24.0%of revenue; Core EPS3 increased to  4.98. R&D update: Doxecitine and doxribtimine in thymidine Kinase 2 deficiency filed in U.S. – with granted priority review - and in EU; 1st phase 3 with positive results for dapirolizumab pegol in systemic lupus erythematosus , 2nd phase 3 started; Phase 2a study in atopic dermatitis with UCB9741/galvokimig showed positive and convincing data. Sustainability with significant improvement in patient access, CO2 reduction and ESG ratings. Financial guidance for 2025: Revenue expected to grow to  6.5-6.7 billion, adjusted EBITDA2 to re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/growth-path-decade-plus-strong-120000933.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/growth-path-decade-plus-strong-120000933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSO","SLE","BK4077","CET","BK4007","AS","UCBJF","BK4204","UCBJY","BK4202","BK4111"],"gpt_icon":0},{"id":"2512443527","title":"This Super League Enterprise Insider Increased Their Holding By 46% Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2512443527","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512443527?lang=en_us&edition=fundamental","pubTime":"2025-02-20 19:01","pubTimestamp":1740049268,"startTime":"0","endTime":"0","summary":"Looking at Super League Enterprise, Inc.'s  insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.Check out our latest analysis for Super League Enterprise. Super League Enterprise Insider Transactions Over The Last Year. The fact that there have been no Super League Enterprise insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. Insiders own shares in Super League Enterprise and we see no evidence to suggest they are worried about the future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-enterprise-insider-increased-110108845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2511454270","title":"Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2511454270","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511454270?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:00","pubTimestamp":1739451600,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River’s immunology expertise to refine study paramet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/13/3025817/0/en/Conduit-Pharmaceuticals-Partners-with-Charles-River-in-Clinically-Relevant-Systemic-Lupus-Erythematosus-Model.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2511580714","title":"Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2511580714","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511580714?lang=en_us&edition=fundamental","pubTime":"2025-02-13 05:01","pubTimestamp":1739394060,"startTime":"0","endTime":"0","summary":"Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein. Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028. Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need. Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET. Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – GalapagosNV , a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today reported its financial results for the full year 2024 and provided an update on the fourth quarter 2024 and its year-to-date performance.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galapagos-reports-full-2024-results-210100294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","GLPG","SLE","BK4588","ORR","FL","BK4139","BK4585","BK4023","DM","BK4546","BL","BK4094","BK4077","LU0757428866.USD","LU1815336091.USD"],"gpt_icon":0},{"id":"2510878320","title":"Royalty Pharma Announces R&D Funding Collaboration With Biogen","url":"https://stock-news.laohu8.com/highlight/detail?id=2510878320","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510878320?lang=en_us&edition=fundamental","pubTime":"2025-02-12 19:30","pubTimestamp":1739359800,"startTime":"0","endTime":"0","summary":"Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb.  12, 2025  ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/12/3024862/0/en/Royalty-Pharma-Announces-R-D-Funding-Collaboration-With-Biogen.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1894683348.USD","BK4550","LU0321505439.SGD","LU0985481810.HKD","IE00B19Z9Z06.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU0289739699.SGD","PFE","SG9999013999.USD","SLE","IE00B894F039.SGD","LU1894683264.USD","SGXZ57979304.SGD","IE00B19Z9P08.USD","LU0306807586.USD","IE00B19Z3581.USD","BK4139","IE00BBT3K403.USD","LU0321505868.SGD","BK4007","BK4534","BK4592","LU0122379950.USD","IE000M9KFDE8.USD","LU0889565916.HKD","SG9999002224.SGD","SG9999003800.SGD","SG9999001176.USD","LU0234572021.USD","LU1023059063.AUD","LU0306806265.USD","LU0456855351.SGD","LU1066053197.SGD","BK4599","BK4077","BK4585","LU0225771236.USD","LU0058720904.USD","LU1883839398.USD","BK4532","SG9999011175.SGD","BK4533","IE00BLSP4452.SGD","BK4581","LU1066051498.USD","BIIB","LU1057294990.SGD","BK4568"],"gpt_icon":1},{"id":"2510575493","title":"CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2510575493","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510575493?lang=en_us&edition=fundamental","pubTime":"2025-02-12 05:01","pubTimestamp":1739307660,"startTime":"0","endTime":"0","summary":"-2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY continues to gain momentum; new cell patient collection initiations expected to signific","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/11/3024578/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","IE00B19Z9Z06.USD","SLE","LU0079474960.USD","VRTX","LU2236285917.USD","LU2324357040.USD","IE0002141913.USD","MACE","ADC","CRSP","AGT","LU0256863811.USD","IE00B4R5TH58.HKD","LU1585245621.USD","LU0109394709.USD","LU0058720904.USD","BK4585","BK4022","LU1430594728.SGD","BK4533","IE00B2B36J28.USD","VERX","BK4139","IE0002270589.USD","BK4183","LU2456880835.USD","LU1861559042.SGD","AHP","LU1093756168.USD","LU0757428866.USD","LU2362540622.SGD","UAE","LU0289739699.SGD","LU1035775433.USD","IE00BJT1NW94.SGD","BK4230","LU0061475181.USD","LU1559883803.SGD","LENZ","LU2462157665.USD","LU0823416689.USD","IE00B19Z3B42.SGD","KSA","LU0889565916.HKD","LU0417517546.SGD","LU2362541273.HKD","BK4231","CAR","BK4157"],"gpt_icon":0},{"id":"2509407237","title":"Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407237","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509407237?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:10","pubTimestamp":1738757400,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif. & BOSTON, February 05, 2025----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration  has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with refractory systemic lupus erythematosus  with extrarenal involvement.Fast Track Designation is a process designed to facilitate development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.This press release contains \"forward-looking statements\" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"target,\" \"would\" and similar expressions are intende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-receives-fda-fast-121000035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0124384867.USD","LU1978683503.SGD","LU0444971666.USD","LU1992135472.HKD","LU0082616367.USD","LU2458330169.SGD","CAR","BK4230","LU0724618433.USD","BK4588","BK4077","LU1815336760.USD","LU2237438978.USD","LU1670710588.SGD","LU1074936037.SGD","LU1670710661.SGD","LU1861219969.SGD","SLE","BK4605","LU2458330243.SGD","LU0314104364.USD","IE00B5949003.HKD","LU1670711040.USD","LU2237443549.SGD","LU2298322129.HKD","BK4585","LU2237443978.SGD","IE00BZ199S13.USD","LU1670711123.USD","LU2272731782.SGD","ACET","IE0009356076.USD","FAST","ADI","LU2237443382.USD","IE00BD6J9T35.USD","LU1861214812.USD","LU1244550221.USD","LU0109392836.USD","LU1992135399.USD","LU1244550577.SGD","LU2237443622.USD","BK4141","LU0889565833.HKD","LU0719512351.SGD","LU1642822529.SGD","BK4512","LU2272731600.USD","BK4515","BK4139"],"gpt_icon":0},{"id":"2509407986","title":"Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407986","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509407986?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:05","pubTimestamp":1738757100,"startTime":"0","endTime":"0","summary":"- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/05/3021061/0/en/Zenas-BioPharma-Announces-Key-2024-Accomplishments-and-2025-Business-Objectives-to-Support-the-Global-Development-and-Commercialization-of-Therapies-for-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139","BK4077","SLE"],"gpt_icon":0},{"id":"2509552283","title":"Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2509552283","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509552283?lang=en_us&edition=fundamental","pubTime":"2025-02-05 19:38","pubTimestamp":1738755480,"startTime":"0","endTime":"0","summary":"Exagen Inc.  shares soared 29.4% in the last trading session to close at $5.02. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 14.5% gain over the past four weeks.The recent surge in Exagen shares can be attributed to the ongoing positive trend that the company is witnessing post its announcement of a solid fourth quarter and full year 2024 preliminary results in January. XGN also received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus  and rheumatoid arthritis  biomarker assays. Also, XGN is witnessing a positive earnings estimate revision as loss estimate for 2025 improved from 70 cents to 58 cents in the past 30 days. As a result, investors are anticipating continued growth in earnings and revenue, which is expected to drive the stock’s upward momentum in the coming quarters.This company is expected to post quarterly loss of $0.27 per share in i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-exagen-xgn-29-113800709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAPR","BK4077","SLE","RA","XGN","BK4139"],"gpt_icon":0},{"id":"2505312430","title":"Jail, caning for teen in SLE bike chase that killed LTA officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505312430","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505312430?lang=en_us&edition=fundamental","pubTime":"2025-01-23 11:37","pubTimestamp":1737603420,"startTime":"0","endTime":"0","summary":"The teen knew that he was wanted, and accelerated away from the late LTA officer Zdulfika Ahakasah to escape arrest.","market":"us","thumbnail":"https://dam.mediacorp.sg/image/upload/s--bpHb1jwL--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2024/09/20/lta%20enforcement%20officer%20accident.jpg?itok=L-kkc82X","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--bpHb1jwL--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2024/09/20/lta%20enforcement%20officer%20accident.jpg?itok=L-kkc82X"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/jail-caning-teen-sle-bike-chase-killed-lta-officer-4891041","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2505145229","title":"RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published","url":"https://stock-news.laohu8.com/highlight/detail?id=2505145229","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505145229?lang=en_us&edition=fundamental","pubTime":"2025-01-21 20:00","pubTimestamp":1737460800,"startTime":"0","endTime":"0","summary":"Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without requiring prior therapeutic steps or authorization. Additionally, new data describing the foundations for Talicia's recent FDA-approved label change to a more convenient three-times daily  \"breakfast, lunch, and dinner\" dosing routine, supporting patient adherence, has been published in the Journal of Clinical Pharmacology. The published data describe the use of physiologically-based pharmacokinetic  modeling and simulation to demonstrate pharmacokinetic equivalence of the TID regimen to the previous every 8-hour  dosing regimen. H. pylori infection affects approximately 35% of the U.S. adult population and is classified by the World Health Organization  as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer and a major risk factor for peptic ulcer disease. The result of a successful collaboration with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhills-talicia-adds-8-million-120000783.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhills-talicia-adds-8-million-120000783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","BK4535","BNTX","BK4144","ITT","BK4124","BK4570","BK4161","BK4588","LU0053671581.USD","RDHL","BK4548","BK4568","BK4139","BK4077","PPI","SEER","TEN","BK4585","LU0054578231.USD","BK4551","BK4007","SLE"],"gpt_icon":0},{"id":"2503630815","title":"Press Release: Autolus Therapeutics Provides Business Updates and 2025 Overview","url":"https://stock-news.laohu8.com/highlight/detail?id=2503630815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503630815?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769600,"startTime":"0","endTime":"0","summary":"- Ongoing commercial launch of AUCATZYL on track, with 24 treatment centers fully authorized as of January 10. - National Comprehensive Cancer Network adds AUCATZYL to its Clinical Practice Guidelines in Oncology . - Company to provide clinical development program updates, including plans for expansion into autoimmune disease, at April 23 R&D investor event. LONDON, Jan. 13, 2025  -- Autolus Therapeutics plc , a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies to patients, today announces business updates and an overview of 2025 milestones.AUCATZYL was approved by the FDA on November 8, 2024. Autolus expects to complete authorization of the first 30 treatment centers, covering approximately 60% of the identified target patient population, by the end of January 2025. The Company expects to complete authorization of 60 treatment centers, covering approximately 90% of the target patient population, by the end of 2025.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR","ALL","BK4139","CRS","LU0985320562.USD","IE00B19Z4B17.USD","BK4230","SLE","BK4022","BK4232","BK4533","IE0031619046.USD","LU2355687059.USD","BK4006","BK4107","LU1699723380.USD","IE00B66KJ199.SGD","LU1571399168.USD","BK4077","BK4588","LU2065731478.USD","BK4585","IE00B7SZL793.SGD","LENZ","R","AUTL"],"gpt_icon":0},{"id":"2503084153","title":"Autolus Therapeutics Provides Business Updates and 2025 Overview","url":"https://stock-news.laohu8.com/highlight/detail?id=2503084153","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503084153?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769600,"startTime":"0","endTime":"0","summary":"- Ongoing commercial launch of AUCATZYL on track, with 24 treatment centers fully authorized as of January 10th. - National Comprehensive Cancer Network adds AUCATZYL to its Clinical Practice Guidelines in Oncology . - Company to provide clinical development program updates, including plans for expansion into autoimmune disease, at April 23rd R&D investor event. LONDON, Jan. 13, 2025  -- Autolus Therapeutics plc, a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies to patients, today announces business updates and an overview of 2025 milestones.AUCATZYL was approved by the FDA on November 8, 2024. Autolus expects to complete authorization of the first 30 treatment centers, covering approximately 60% of the identified target patient population, by the end of January 2025. The Company expects to complete authorization of 60 treatment centers, covering approximately 90% of the target patient population, by the end of 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/autolus-therapeutics-provides-business-updates-120000588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","IE00B19Z4B17.USD","IE0031619046.USD","CAR","BK4230","BK4588","LU0985320562.USD","BK4077","LU2355687059.USD","ALL","LU2065731478.USD","LU1699723380.USD","SLE","BK4585","BK4107","BK4533","CRS","LU1571399168.USD","IE00B7SZL793.SGD","AUTL","LENZ","IE00B66KJ199.SGD","BK4139","BK4022"],"gpt_icon":0},{"id":"2503004313","title":"Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503004313","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503004313?lang=en_us&edition=fundamental","pubTime":"2025-01-13 08:05","pubTimestamp":1736726700,"startTime":"0","endTime":"0","summary":"-- CB-010 GALLOP Phase 1 trial initiated in lupus -- -- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 -- -- CB-010 ANTLER 2L LBCL and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008079/0/en/Caribou-Biosciences-Initiates-the-CB-010-GALLOP-Phase-1-Trial-in-Lupus-and-Provides-Outlook-for-Multiple-Clinical-Datasets-in-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","SLE","PFS","LU0256863811.USD","LU0868494617.USD","BK4077","CAR","CRBU","BK4585","BK4022","LU0417517546.SGD","BK4211","BK4195","BK4107","BK4539","BK4230"],"gpt_icon":0},{"id":"2503393352","title":"Press Release: Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2503393352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503393352?lang=en_us&edition=fundamental","pubTime":"2025-01-13 01:00","pubTimestamp":1736701200,"startTime":"0","endTime":"0","summary":"Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results. New biomarkers on track for commercial launch in January 2025. Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn. CARLSBAD, Calif., Jan. 12, 2025  -- Exagen Inc. , a leading provider of autoimmune testing, today announced it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus  and rheumatoid arthritis  biomarker assays, with a planned commercial launch in January 2025.  The company also announced preliminary unaudited select financial results for the fourth quarter and full year ended December 31, 2024, in line with prior financial guidance.The company's new SLE and RA biomarkers will be incorporated into the AVISE CTD platform. Collectively, the company expect","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","IE00B3QW5Z07.USD","BK4077","LU0061475181.USD","LU1894683348.USD","RA","LU1883839398.USD","R","IE00B64PRP62.GBP","SLCT","BK4585","IE00BGHQF748.EUR","BK4232","IE0034235188.USD","BK4022","BK4588","BK4135","LU1894683264.USD","XGN","BK4139","STT"],"gpt_icon":0},{"id":"2502085244","title":"Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2502085244","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502085244?lang=en_us&edition=fundamental","pubTime":"2025-01-09 05:10","pubTimestamp":1736370600,"startTime":"0","endTime":"0","summary":"Adicet made significant progress in 2024 and is well-positioned for success in 2025: Advancing Phase 1 clinical trial evaluating ADI-001 across six autoimmune diseases; preliminary data in lupus nephritis  patients anticipated in 1H25, data from other patient cohorts expected in 2H25. Patient enrollment in systemic lupus erythematosus , systemic sclerosis , idiopathic inflammatory myopathy  and stiff person syndrome  expected to be initiated in 1Q25; initiation of patient enrollment in anti-neutrophil cytoplasmic autoantibody  associated vasculitis  expected in 2H25. REDWOOD CITY, Calif. & BOSTON, January 08, 2025----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2025.In September 2024, Adicet presented clinical biomarker data from the Phase 1 GLEAN trial of ADI-001 at the 9th Annual CAR-TCR Summit dem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-provides-corporate-highlights-211000326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACET","BK4139","SLE","BK4077","BK4022","CAR","IIM","BK4230"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":101,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"SLE","fiscalQuarterEnding":"2025/03","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-03-28","symbol":"SLE","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2024-11-14","symbol":"SLE","fiscalQuarterEnding":"2024/09","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.54},{"market":"US","date":"2024-08-14","symbol":"SLE","fiscalQuarterEnding":"2024/06","expectedEps":-0.62,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.6},{"market":"US","date":"2024-05-15","symbol":"SLE","fiscalQuarterEnding":"2024/03","expectedEps":-1.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":1}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1694232000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2025-06-13","current":-0.226363,"percent":0.703614,"low":-0.555206,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"high":-0.044016,"avg":-0.274466,"sd":0.104139,"marketCap":3532387},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387}],"updateTime":1750143594778}}}